

# INDEX

## A

Active targeting ..... 71, 96, 145, 146, 159  
Airway ..... 180, 182, 186  
Aminoglycosides ..... 5, 9, 10  
Antibodies ..... 28–30, 71, 72, 74, 75, 81, 83,  
88, 92, 93, 96, 97, 111, 122, 132, 137, 138, 146–154,  
186, 212, 217–221  
Astrocytes ..... 49, 72, 79, 83, 87, 123

## B

Bacteria ..... 25–34, 72, 74–87,  
89, 90, 92–94  
Bacteria-based therapy ..... 25–34  
Bacteria-nanoparticle complex ..... 33  
Bacteriophage ..... 71–76  
Biodistribution ..... 59, 180, 191–199  
Bioluminescence imaging ..... 56  
Biomaterials ..... 17  
Biopanning ..... 72, 74, 78–86, 92  
Blood-brain barrier (BBB) ..... 17, 111, 116, 117, 214

## C

Cancer ..... 3, 6, 9, 25, 29, 31, 32, 34, 38,  
49–57, 59, 62–64, 66, 95–97, 104, 105, 131, 145, 160,  
162–164, 167, 168, 170, 172–175, 180, 208, 210, 217,  
221, 222  
Cancer stem cells ..... 59–67  
Cancer therapeutics ..... 25–34, 131, 145, 159  
Carrier-mediate agents (CMA) ..... 201–222  
CD44 ..... 60, 95–108  
Combination therapy ..... 59  
Controlled release ..... 180  
Convection-enhanced delivery (CED) ..... 18, 122, 130

## D

Diffusion ..... 111, 132–135, 137, 139, 160,  
161, 169–172, 174, 175, 208, 215, 221  
Diglycidyl ethers ..... 3–16  
Domain antibody (dAb) ..... 71, 72, 74, 75, 80–83,  
85, 86, 89–94  
Drug delivery ..... 17, 26, 59–67, 71,  
121, 179–189

## E

Electroporation ..... 38–42, 44, 45  
Enzyme-linked immunosorbant assay  
(ELISA) ..... 74, 85–89, 145–156, 181, 185, 186  
Exosome ..... 37, 40  
Extracellular vesicles (EV) ..... 37–46

## F

Fibrin scaffolds ..... 50, 53, 54  
Finite element modeling ..... 123, 137  
Flow cytometry ..... 180, 186, 187, 217–220  
Focused ultrasound (FUS) ..... 112, 113, 115, 116

## G

Gene delivery ..... 3–16, 96, 145, 146  
Gene therapy ..... 3  
Glioblastoma ..... 49, 50, 123

## H

Hyaluronic acid (HA) ..... 60–63, 65, 96–101, 106

## I

Immune system ..... 221  
Inflammation ..... 3, 208  
Intranasal administration ..... 179, 180, 182  
Intratumoral transport ..... 25, 26

## L

Lipid nanoparticles (LNP) ..... 95–101, 103–106, 108  
Liposomes ..... 96, 100, 203

## M

Mass transport ..... 133, 160  
Mechanical homogenization ..... 191  
Mesenchymal stem cell (MSC) ..... 49–57  
Microbubble ..... 111, 116, 117  
Microfluidic ..... 159–175  
MicroRNA (miRNA) ..... 38, 95, 99, 101,  
103–105, 108  
Molecular targeting ..... 145, 146  
Mononuclear phagocyte system (MPS) ..... 202, 203, 220

**N**

Nanoparticles .....17–23, 26, 29, 30, 33, 34,  
 39, 59–67, 95, 99, 101, 103–105, 108, 111, 122,  
 145–156, 159, 161, 166, 170–175, 179–189, 201,  
 203, 206, 209, 210, 217

Nanoparticle transport..... 159, 161, 166, 170–175

**P**

Phage display .....71–94

Pharmacodynamics (PD) .....201–222

Pharmacokinetics (PK).....59, 180, 191, 201–222

Poly(d,l-lactide-co-glycolide) (PLGA)..... 17–23, 33,  
 60–64, 188

Polymers .....3–19, 21, 26, 50, 54, 60, 61, 66, 160

Polyplex ..... 3, 12, 15

**R**

Responsiveness .....26, 222

**S**

Short interfering RNA (siRNA) .....38, 39, 41–43,  
 45, 46, 96, 101

Single chain antibody fragments (scFv).....71, 72, 74,  
 75, 80–82, 85, 86, 89–94

Small molecules..... 38, 39, 42–44, 72, 193,  
 202, 203, 220, 221

Surface functionalization .....96, 98–101, 106

**T**

Targeted drug delivery.....59–67,  
 71, 121

Therapeutic ultrasound..... 111–117

Tissue homogenization..... 191–199

Tumor engineering .....162

Tumor microenvironment.....159, 161, 166,  
 170, 171, 173, 175, 221, 222

Tumor-targeting bacteria.....26